Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.83 USD | +12.93% | +35.71% | +636.73% |
Apr. 11 | Sector Update: Health Care Stocks Decline Thursday Afternoon | MT |
Apr. 11 | Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 281M |
---|---|---|---|---|---|
Net income 2024 * | -41M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-11.9
x | P/E ratio 2025 * |
-
| Employees | 42 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.01% |
1 day | +12.93% | ||
1 week | +53.62% | ||
Current month | +53.62% | ||
1 month | +63.10% | ||
3 months | +766.40% | ||
6 months | +1,077.17% | ||
Current year | +636.73% |
Managers | Title | Age | Since |
---|---|---|---|
Paul-Peter Tak
CEO | Chief Executive Officer | 64 | 20-08-31 |
Founder | 66 | 01-12-31 | |
Charles Schoch
DFI | Director of Finance/CFO | 39 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Papa
BRD | Director/Board Member | 68 | 22-08-07 |
Edward Benz
BRD | Director/Board Member | 78 | 17-08-31 |
Paul Manning
CHM | Chairman | 68 | 18-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 10.83 | +12.93% | 1,148,935 |
24-05-07 | 9.59 | +8.36% | 765,135 |
24-05-06 | 8.85 | -1.88% | 1,884,091 |
24-05-03 | 9.02 | +7.00% | 1,008,831 |
24-05-02 | 8.43 | +5.64% | 1,258,306 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+636.73% | 281M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- CADL Stock